Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Boniva, Requip TV Advertising Campaigns Debut

This article was originally published in The Pink Sheet Daily

Executive Summary

Roche and GlaxoSmithKline are running TV commercials for the osteoporosis therapy Boniva (ibandronate), GSK said

You may also be interested in...

GSK/Roche's Boniva Print Ad Uses Question-And-Answer Brief Summary

Print campaign for the osteoporosis agent uses a reprint of the patient information sheet, which is in a Q&A format, instead of traditional brief summary format. The campaign highlights Boniva's unique once-monthly dosing regimen.

GSK Predicts Significant Restless Legs Market For Requip

The supplemental NDA for the Parkinson's therapy marks the first drug approval for restless legs syndrome. GSK says one in 10 adults have the condition.

Roche/GSK Boniva Once-Monthly To Be Launched In April

The companies are planning "substantial" DTC ad campaigns, Roche says. FDA approves supplemental NDA for once-monthly ibandronate for treatment of osteoporosis in postmenopausal women. Boniva will be priced competitively to the currently marketed bisphosphonates, Roche says.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts